Glioma is the most common primary cancer of the central nervous system, and around 50%
of patients present with the most aggressive form of the disease, glioblastoma. Conventional …

In patients with certain hematologic malignancies, the use of autologous T cells genetically
modified to express chimeric antigen receptors (CARs) has led to unprecedented clinical …

Tumour-associated macrophages (TAMs) are enriched in glioblastoma multiformes (GBMs)
that contain glioma stem cells (GSCs) at the apex of their cellular hierarchy. The correlation …

There has been no significant improvements for immune checkpoint inhibitors since its first
use. Tumour-associated macrophages (TAMs) are critical mediators in the PD-1/PD-L1 axis …

Glioblastoma (GBM) is the most devastating brain tumor, with associated poor prognosis.
Despite advances in surgery and chemoradiation, the survival of afflicted patients has not …

Glioblastoma is the most common and most malignant primary adult human brain tumour.
Diagnosis of glioblastoma carries a dismal prognosis. Treatment resistance and tumour …

The central nervous system (CNS) historically has been considered an immune-privileged
organ, lacking a lymphatic system and shielded from the circulatory system by the blood …

Microglia have long been ignored by neurooncologists. This has changed with the
realization that microglial cells not only occur within and around brain tumors but also …

While the central nervous system is considered an immunoprivileged site and brain tumors
display immunosuppressive features, both innate and adaptive immune responses affect …

Immune checkpoint inhibitors propelled the field of oncology with clinical responses in many
different tumor types. Superior overall survival over chemotherapy has been reported in …